---
document_datetime: 2025-11-23 08:03:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/krystexxa.html
document_name: krystexxa.html
version: success
processing_time: 0.1066596
conversion_datetime: 2025-12-28 08:47:49.944178
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Krystexxa

[RSS](/en/individual-human-medicine.xml/66095)

##### Withdrawn

This medicine's authorisation has been withdrawn

pegloticase

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Krystexxa](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 30 June 2016 the European Commission withdrew the marketing authorisation for Krystexxa (pegloticase) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Crealta Pharmaceuticals Ireland Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. Krystexxa was granted marketing authorisation in the EU on 8 January 2013 for treatment of chronic gout. The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for Krystexxa is updated accordingly to indicate that the marketing authorisation is no longer valid.

Krystexxa : EPAR - Summary for the public

Adopted

Reference Number: EMA/CHMP/17512/2013

English (EN) (521.09 KB - PDF)

**First published:** 01/02/2013

**Last updated:** 22/07/2016

[View](/en/documents/overview/krystexxa-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-823)

български (BG) (1.13 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/bg/documents/overview/krystexxa-epar-summary-public_bg.pdf)

español (ES) (1.02 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/es/documents/overview/krystexxa-epar-summary-public_es.pdf)

čeština (CS) (1.07 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/cs/documents/overview/krystexxa-epar-summary-public_cs.pdf)

dansk (DA) (987.73 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/da/documents/overview/krystexxa-epar-summary-public_da.pdf)

Deutsch (DE) (988.53 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/de/documents/overview/krystexxa-epar-summary-public_de.pdf)

eesti keel (ET) (1.03 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/et/documents/overview/krystexxa-epar-summary-public_et.pdf)

ελληνικά (EL) (1.22 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/el/documents/overview/krystexxa-epar-summary-public_el.pdf)

français (FR) (990.13 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/fr/documents/overview/krystexxa-epar-summary-public_fr.pdf)

italiano (IT) (975.29 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/it/documents/overview/krystexxa-epar-summary-public_it.pdf)

latviešu valoda (LV) (1.15 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/lv/documents/overview/krystexxa-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (1022.33 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/lt/documents/overview/krystexxa-epar-summary-public_lt.pdf)

magyar (HU) (1.06 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/hu/documents/overview/krystexxa-epar-summary-public_hu.pdf)

Malti (MT) (1.13 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/mt/documents/overview/krystexxa-epar-summary-public_mt.pdf)

Nederlands (NL) (987.81 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/nl/documents/overview/krystexxa-epar-summary-public_nl.pdf)

polski (PL) (1.07 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/pl/documents/overview/krystexxa-epar-summary-public_pl.pdf)

português (PT) (1.02 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/pt/documents/overview/krystexxa-epar-summary-public_pt.pdf)

română (RO) (1020.33 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/ro/documents/overview/krystexxa-epar-summary-public_ro.pdf)

slovenčina (SK) (1.07 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sk/documents/overview/krystexxa-epar-summary-public_sk.pdf)

slovenščina (SL) (1.12 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sl/documents/overview/krystexxa-epar-summary-public_sl.pdf)

Suomi (FI) (985.93 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/fi/documents/overview/krystexxa-epar-summary-public_fi.pdf)

svenska (SV) (983.73 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sv/documents/overview/krystexxa-epar-summary-public_sv.pdf)

## Product information

Krystexxa : EPAR - Product Information

English (EN) (1.41 MB - PDF)

**First published:** 01/02/2013

**Last updated:** 22/07/2016

[View](/en/documents/product-information/krystexxa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-373)

български (BG) (2.54 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/bg/documents/product-information/krystexxa-epar-product-information_bg.pdf)

español (ES) (1.41 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/es/documents/product-information/krystexxa-epar-product-information_es.pdf)

čeština (CS) (2.15 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/cs/documents/product-information/krystexxa-epar-product-information_cs.pdf)

dansk (DA) (1.4 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/da/documents/product-information/krystexxa-epar-product-information_da.pdf)

Deutsch (DE) (1.44 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/de/documents/product-information/krystexxa-epar-product-information_de.pdf)

eesti keel (ET) (1.4 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/et/documents/product-information/krystexxa-epar-product-information_et.pdf)

ελληνικά (EL) (2.63 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/el/documents/product-information/krystexxa-epar-product-information_el.pdf)

français (FR) (1.48 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/fr/documents/product-information/krystexxa-epar-product-information_fr.pdf)

hrvatski (HR) (1.48 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/hr/documents/product-information/krystexxa-epar-product-information_hr.pdf)

íslenska (IS) (1.43 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/is/documents/product-information/krystexxa-epar-product-information_is.pdf)

italiano (IT) (1.5 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/it/documents/product-information/krystexxa-epar-product-information_it.pdf)

latviešu valoda (LV) (2.21 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/lv/documents/product-information/krystexxa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.54 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/lt/documents/product-information/krystexxa-epar-product-information_lt.pdf)

magyar (HU) (2.18 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/hu/documents/product-information/krystexxa-epar-product-information_hu.pdf)

Malti (MT) (2.27 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/mt/documents/product-information/krystexxa-epar-product-information_mt.pdf)

Nederlands (NL) (1.42 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/nl/documents/product-information/krystexxa-epar-product-information_nl.pdf)

norsk (NO) (1.41 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/no/documents/product-information/krystexxa-epar-product-information_no.pdf)

polski (PL) (2.18 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/pl/documents/product-information/krystexxa-epar-product-information_pl.pdf)

português (PT) (1.45 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/pt/documents/product-information/krystexxa-epar-product-information_pt.pdf)

română (RO) (1.48 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/ro/documents/product-information/krystexxa-epar-product-information_ro.pdf)

slovenčina (SK) (2.16 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sk/documents/product-information/krystexxa-epar-product-information_sk.pdf)

slovenščina (SL) (2.13 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sl/documents/product-information/krystexxa-epar-product-information_sl.pdf)

Suomi (FI) (1.41 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/fi/documents/product-information/krystexxa-epar-product-information_fi.pdf)

svenska (SV) (1.41 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sv/documents/product-information/krystexxa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010046/201501 30/06/2016

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Krystexxa : EPAR - All Authorised presentations

English (EN) (931.95 KB - PDF)

**First published:** 01/02/2013

**Last updated:** 22/07/2016

[View](/en/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-661)

български (BG) (1.03 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/bg/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_bg.pdf)

español (ES) (932.55 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/es/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (985.9 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/cs/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (991.86 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/da/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (932.25 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/de/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (932.05 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/et/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (527.69 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/el/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_el.pdf)

français (FR) (932.36 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/fr/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (932.41 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/is/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (991.66 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/it/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (987.38 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/lv/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (959.88 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/lt/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (969.58 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/hu/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (1.02 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/mt/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (991.98 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/nl/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (932.37 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/no/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_no.pdf)

polski (PL) (1.02 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/pl/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_pl.pdf)

português (PT) (932.67 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/pt/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_pt.pdf)

română (RO) (959.71 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/ro/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (1.01 MB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sk/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (969.12 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sl/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (991.27 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/fi/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (992.26 KB - PDF)

**First published:**

01/02/2013

**Last updated:**

22/07/2016

[View](/sv/documents/all-authorised-presentations/krystexxa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Krystexxa Active substance pegloticase International non-proprietary name (INN) or common name pegloticase Therapeutic area (MeSH) Gout Anatomical therapeutic chemical (ATC) code M04AX02

### Pharmacotherapeutic group

Antigout preparations

### Therapeutic indication

Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

## Authorisation details

EMA product number EMEA/H/C/002208 Marketing authorisation holder

Crealta Pharmaceuticals Ireland Limited

Commercial House

Marketing authorisation issued 08/01/2013 Withdrawal of marketing authorisation 30/06/2016 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Krystexxa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1005.03 KB - PDF)

**First published:** 01/12/2014

**Last updated:** 22/07/2016

[View](/en/documents/procedural-steps-after/krystexxa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Krystexxa-PSUSA-00010046-201501 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/697925/2015

English (EN) (1003.14 KB - PDF)

**First published:** 25/01/2016

**Last updated:** 22/07/2016

[View](/en/documents/scientific-conclusion/krystexxa-psusa-00010046-201501-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Krystexxa : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/697253/2012

English (EN) (5.41 MB - PDF)

**First published:** 01/02/2013

**Last updated:** 22/07/2016

[View](/en/documents/assessment-report/krystexxa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Krystexxa

Adopted

Reference Number: EMA/CHMP/672303/2012

English (EN) (970.17 KB - PDF)

**First published:** 19/10/2012

**Last updated:** 22/07/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-krystexxa_en.pdf)

#### More information on Krystexxa

- [EMEA-000293-PIP02-10-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000293-pip02-10-m01)

**This page was last updated on** 22/07/2016

## Share this page

[Back to top](#main-content)